Siwa Therapeutics

From H+Pedia
Revision as of 09:11, 28 April 2021 by Uglibo (talk | contribs) (Created page with "'''Siwa Therapeutics''' is an American biotech company that has developed an antibody treatment that targets senescent (aged) cells and ot...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Siwa Therapeutics is an American biotech company that has developed an antibody treatment that targets senescent (aged) cells and other unhealthy cells.[1][2] The antibody has been shown to target age-related diseases such as Alzheimer's and cancer, and it has improved muscle growth in old mice.[1] MIT Technology Review called the company a 'key player' in its 10 Breakthrough Technologies of 2020, and Forbes named it one of three "senolytics companies to watch".[1]

References

  1. 1.0 1.1 1.2 "Home". Siwa Therapeutics. Retrieved 28 April 2021. "SIWA has developed a proprietary humanized monoclonal antibody, 318H, that selectively targets a biomarker on cells exhibiting a combination of: (a) an abnormally high level of glycolysis (Warburg effect) and (b) oxidative stress. Cells with our marker include specifically (1) cancer cells, (2) senescent cells, and (3) microbially-infected cells (viruses, bacteria and at least some parasites). [...] We have shown 318H binding in vitro to all types of cancer cells from aggressive cancers, e.g. human pancreatic cancer and gliomas as well as to human SCs from numerous tissues, including e.g., Alzheimer’s and Parkinson’s diseases, osteoarthritic cells, and diseased renal cells. We also have shown 318H binding to cells infected by SARS-CoV-2 (COVID-19) and Influenza A. [...] We have shown 318H binding in vitro to all types of cancer cells from aggressive cancers, e.g. human pancreatic cancer and gliomas as well as to human SCs from numerous tissues, including e.g., Alzheimer’s and Parkinson’s diseases, osteoarthritic cells, and diseased renal cells. [...] In February 2020, SIWA was named a “key player” in Anti-Aging Drugs by the MIT Technology Review in its prestigious list of the 10 Breakthrough Technologies of 2020. In September 2018, Forbes named SIWA as one of 3 senolytics companies to watch (“Senolytic Therapies and the Quest to Cure Aging”)."
  2. "Siwa Therapeutics". Siwa Therapeutics. Retrieved 28 April 2021. "SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells."

External links